Neumora Therapeutics will host a roundtable on the potential of Navacaprant in neuropsychiatric disorders on Sept. 12. The discussion will focus on the role of kappa opioid receptor antagonists in neuropsychiatry.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing